{"classes":[{"categories":[{"measurements":[{"groupId":"OG002","lowerLimit":"0.4","upperLimit":"5.0","value":"1.8"},{"groupId":"OG003","lowerLimit":"0.7","upperLimit":"2.1","value":"2.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"}],"units":"Participants"}],"description":"Time from date of treatment start until the date of first objective documentation of disease-relapse.","dispersionType":"Full Range","groups":[{"description":"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.\n\nPhase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.\n\nSelinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.","id":"OG000","title":"Phase I Group 1 Selinexor + Sorafenib"},{"description":"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.\n\nPhase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle.","id":"OG001","title":"Phase I Group 2 Selinexor + Sorafenib"},{"description":"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSelinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.","id":"OG002","title":"Cohort 1 (FLT3-ITD Inhibitor Failure Cohort)"},{"description":"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSelinexor: Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.\n\nPhase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I.\n\nSorafenib: Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.\n\nPhase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.","id":"OG003","title":"Cohort 2 (FLT3-ITD Inhibitor Naive Cohort)"}],"paramType":"MEDIAN","populationDescription":"Event Free Survival was not an objective outlined for participants in Phase I Group's 1 and 2, therefore overall survival was not done for these participants. Of the seven participants in cohort 1, one participant was not evaluable for response. Of the three participants in cohort 2, one participant was not evaluable for response.","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":"Event Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}